![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With
Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240
|
|
|
EACS 2023 oct 20
Antonella Castagna,1 Cristina Mussini,2 Josep M. Llibre,3 Andrea Antinori,4 Manyu Prakash,5 Amy Pierce,6 Jose R. Castillo-Mancilla,6 Allan R. Tenorio,6 Marcia Wang,7 Fangfang Du,7 Andrew Clark,5 Max Lataillade8
1Vita-Salute San Raffaele University, Milan, Italy; 2Clinic of Infectious Diseases, AOU Policlinico, and University of Modena and Reggio Emilia, Modena, Italy; 3Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 4National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy; 5ViiV Healthcare, Brentford, UK; 6ViiV Healthcare, Durham, NC, USA; 7GSK, Collegeville, PA, USA; 8ViiV Healthcare, Branford, CT, USA
![1024231](../images/102423/102423-18/1024231.gif)
![1024232](../images/102423/102423-18/1024232.gif)
![1024233](../images/102423/102423-18/1024233.gif)
![1024234](../images/102423/102423-18/1024234.gif)
![1024235](../images/102423/102423-18/1024235.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|